Guided ultrasound to deliver drugs to metastatic brain lesions in breast cancer patients｜《Science·Translational Medicine》

Click on the blue text above to follow our study of four Her2-positive breast cancer patients with brain metastases.
Researchers used magnetic resonance guided ultrasound (MRgFUS) to temporarily open the blood-brain barrier and transfer the monoclonal antibody trastuzumab The monoclonal antibody is delivered to specific brain lesions
.

This proof-of-concept study by Ying Meng and colleagues may stimulate the possibility of using this technology to target large therapeutic molecules that are usually blocked by the blood-brain barrier to brain tumors and other neurological diseases
.

The results of this study are good news for Metastatic Breast Cancer Awareness Day (October 13), because the prevalence of brain metastases in patients with Her2-positive breast cancer is increasing and is associated with higher morbidity and mortality, but only Very few systemic treatments
.

Low-dose MRgFUS temporarily increases the permeability of the blood-brain barrier and can be precisely positioned to open up treatment areas, such as the brain stem, cranial nucleus, and cerebellum, which are not always suitable for surgery or radiation therapy
.

This procedure significantly increases the delivery of antibodies to the target lesion and reduces the patient's tumor size
.

The patient received treatment during the outpatient clinic, and there were no serious adverse reactions related to the treatment
.

Welcome to follow the Science official public account.
Click "Read the original text" below to visit the original English page.
If you like this content, click "Like".